Athira Pharma is focused on developing innovative small molecule therapeutics aimed at enhancing neuronal health through the modulation of the hepatocyte growth factor (HGF) system. Their proprietary drug discovery platform is designed to create novel therapeutic candidates that target a range of neurological diseases, including Alzheimer’s and Parkinson’s diseases. The company’s lead product candidates, such as Fosgonimeton (ATH-1017) and ATH-1105, are engineered to promote neuroprotection, regeneration, and potentially modify the progression of neurodegenerative conditions. Preclinical studies have demonstrated that these compounds can reduce inflammation, improve motor and nerve function, and enhance cognitive performance in various models of disease.

Athira's approach emphasizes the importance of the HGF signaling pathway in neuronal repair and protection. Their research indicates that enhancing this pathway can lead to significant therapeutic benefits, including the reduction of neurodegeneration and the promotion of neuronal survival. The company is currently conducting clinical trials to evaluate the safety and efficacy of its product candidates, with a commitment to advancing treatments that can improve the quality of life for patients suffering from debilitating neurological disorders. Through ongoing research and development, Athira Pharma aims to bring forward therapies that address unmet medical needs in the field of neurodegeneration.

United States

At Athira, we aim to restore neuronal health for those suffering from neurological diseases, including Alzheimer’s, so that patients can regain their memories, lives, and family relationships.

Central Nervous System (CNS)

Metabolic Diseases

Nervous System Diseases

Pathological Conditions

Athira Pharma

Dementia

Parkinson's disease

<p class="font_7">ATH-1017 is a small molecule therapeutic specifically designed to enhance the activity of Hepatocyte Growth Factor (HGF) and its receptor, MET, which are expressed in normal central nervous system function, in order to impact neurodegeneration and regenerate brain tissue. In addition to Alzheimer’s disease, ATH-1017 is designed to address the broader dementia population, including Parkinson’s disease dementia. Athira’s completed Phase 1a/b clinical trials of ATH-1017 for the treatment of Alzheimer's disease established that the treatment was generally well tolerated at all tested doses. Measures evaluating brain function with quantitative electroencephalogram (qEEG) also produced a strong suite of translational data. Additionally, a statistically significant improvement in Event-Related Potential (ERP) P300 latency, an objective measure of working memory processing speed, was noted in patients with Alzheimer’s disease following multiple dose treatments with ATH-1017 compared with those receiving placebo.</p>

Fosgonimeton (ATH-1017) 

Amyotrophic lateral sclerosis

ATH-1105

Alzheimer's disease

<p class="font_7">ATH-1017 is a small molecule therapeutic specifically designed to enhance the activity of Hepatocyte Growth Factor (HGF) and its receptor, MET, which are expressed in normal central nervous system function, in order to impact neurodegeneration and regenerate brain tissue. In addition to Alzheimer’s disease, ATH-1017 is designed to address the broader dementia population, including Parkinson’s disease dementia.&nbsp;</p>

Bothell, Washington, United States of America

Athira Pharma

Company Details